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http://dx.doi.org/10.1016/j.ccr.2014.01.031SUMMARYThe relationships between clonal architecture and functional heterogeneity in acute myeloid leukemia (AML)
samples are not yet clear. We used targeted sequencing to track AML subclones identified by whole-genome
sequencing using a variety of experimental approaches. We found that virtually all AML subclones trafficked
from the marrow to the peripheral blood, but some were enriched in specific cell populations. Subclones
showed variable engraftment potential in immunodeficient mice. Xenografts were predominantly comprised
of a single genetically defined subclone, but there was no predictable relationship between the engrafting
subclone and the evolutionary hierarchy of the leukemia. These data demonstrate the importance of inte-
grating genetic and functional data in studies of primary cancer samples, both in xenograft models and in
patients.INTRODUCTION
Cancer arises through an evolutionary process of somatic muta-
tion and selection. Although it may be depicted as a linear
sequence of mutational events that produces a homogeneous
cell population, tumor evolution is associated with significant in-
tratumoral heterogeneity (reviewed in Swanton, 2012). All cells
in a tumor contain shared somatic mutations that reflect its clonal
origin (the ‘‘founding clone’’), but additionalmutations are present
in subpopulations of cells that define tumor subclones. This het-
erogeneity, and the presence of subclonal alterations, was recog-
nized even in early models of tumor evolution, demonstrating that
subclonal cytogenetic aberrations can define ‘‘sublines’’ within a
tumor (Nowell, 1976)—whichwouldnowbedefinedassubclones.Significance
Although clonal heterogeneity inmany tumor types has been cl
their relationships to ‘‘tumor initiating/stem cells’’ are not yet
found that subclones can correspond to different cellular pop
functional properties in vitro and in immunodeficient mice. Spe
in the subclonal complexity of AML samples; engrafting subcl
do not reliably predict relapse. These studies suggest that en
that functional differences among subclones need to be consNew sequencing technologies have greatly improved the
characterization of genetic heterogeneity in cancer. Previous
work on acute myeloid leukemia (AML) and myelodysplastic
syndromes (MDS) demonstrated that these myeloid disorders
exhibit clonal heterogeneity that evolves upon disease progres-
sion and/or relapse (Ding et al., 2012; Ley et al., 2010; Mardis
et al., 2009;Walter et al., 2012;Welch et al., 2012). Similar obser-
vations have been made in other malignancies. Work from Ger-
linger et al. (2012) found that renal cell carcinomas can show
striking clonal variation within different geographic regions of a
single tumor, and recent analysis of clonal architecture in breast
cancer demonstrated a hierarchy that elucidated the phylogeny
of mutational events within individual tumors (Ding et al., 2012;
Navin et al., 2010; Nik-Zainal et al., 2012; Shah et al., 2009).early demonstrated, the functionality of tumor subclones and
clear. Using acute myeloid leukemia (AML) as a model, we
ulations within a single AML sample and can have different
cifically, xenotransplantation results in a dramatic decrease
ones are not defined by recurrent mutations (e.g., FLT3) and
grafting potential is not uniform among AML subclones and
idered in studies of primary cancer samples.
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Table 1. Features of 19 De Novo AML Samples
UPN AML No. FAB Somatic Fusions and Mutationsa
933124 1 M1 DNMT3A L723fs, FLT3-ITD, NPMc
SMC3 G662C
426980 28 M2 IDH2 R140L, IDH2 R140W
452198 31 M5 DNMT3A R882H, FLT3 D835H,
FLT3-ITD, IDH1 R132H, NPMc,IDH2
R140Q
869586 43 M4 RUNX1 G164fs, WT1 A382fs, PHF6
G288V
161510 54 M2 IDH1 R132H, NRAS G13D, WT1
E143fs
255108 60 M0 FLT3-ITD, NPMc, WT1 e7+1,
STAG2 e21+2
296361 62 M5 DNMT3A R882H, FLT3-ITD, NPMc,
IDH1 R132H
303818 63 M0 SETBP1 D868N, ASXL1 Q588*,
KRAS I36M
348685 70 M4 FLT3-ITD, WT1 R370fs
375182 71 M5 DNMT3A R882H, FLT3-ITD, NPMc
433325 75 M2 CEPBA R343fs, DNMT3A Q515*,
NPMc, NRAS G13D, PTPN11 I545L,
WT1 A381fs, SMC3 T1174I
492687 78 M2 FLT3-ITD, FLT3-D835Y, RUNX1
G305*
498463 79 M1 DNMT3A P718Lb, IDH1 R132C,
NRAS G13D, EZH2 R690H
605322 83 M1 DNMT3A D781G, DNMT3A R320*,
FLT3 D839G, IDH1 R132C, TET2
P1115fs, TET2 E1352V, PTPN11
G503E
708512 87 M4 DNMT3AR882H, FLT3D835E, IDH1
R132H, NPMc, KIT D816V
721214 88 M1 DNMT3A R882H, FLT3-ITD, NPMc
737451 91 M5 DNMT3A R882H, NPMc
809653 93 M1 NRAS G13D, TP53 E286G
852559 94 M1 PICALM-MLLT10 PTPN11 P491L,
PHF6 F214fs
UPN, unique patient number.
aMutations found in significantly mutated genes (Cancer Genome Atlas
Research Network, 2013) are listed, in addition to ASXL1 and SETBP1
variants in AML63.
bHomozygous variant.
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Functional Properties of AML SubclonesIn addition to genetic heterogeneity, functional heterogeneity
also exists within a primary tumor and has largely been studied
in the context of identifying cells capable of initiating tumors
when transferred into immunodeficient mice. However, the rela-
tionship of these initiating cells (also referred to as cancer stem
cells) to the clonal organization of a tumor is not yet clear. Previ-
ous studies of acute lymphoblastic leukemia (ALL) and colorectal
cancer have begun to address this relationship: tumor subclones
can be dynamic with serial passaging, and some display
enhanced engraftment potential (Anderson et al., 2011; Clappier
et al., 2011; Kreso et al., 2013; Notta et al., 2011; Schmitz et al.,
2011). However, studies of leukemia samples have thus far
followed copy number alterations, and/or used ALL samples380 Cancer Cell 25, 379–392, March 17, 2014 ª2014 Elsevier Inc.with single, well-defined initiating events (BCR-ABL1 or ETV6-
RUNX1 gene fusions), or have used distinct clinical subsets
that do not reflect the full spectrum of this disease. In addition,
the regional heterogeneity of solid tumors (Ding et al., 2012;
Gerlinger et al., 2012; Nik-Zainal et al., 2012; Shah et al., 2009;
Sottoriva et al., 2013)may introduce sampling bias when assess-
ing clonal heterogeneity (especially in xenotransplantation
models), making it difficult to generalize the results to other can-
cers. From the studies published to date, it also is not yet clear
whether functional differences among tumor subclones can be
observed beyond these experimental systems or whether they
can be identified directly in patient samples.
In this study, we sought to explore the relationship between
functional and genetic heterogeneity by following genetically
defined subclones under different experimental and biological
conditions in de novo AML samples with a wide range of pheno-
typic and genetic characteristics.
RESULTS
Sequencing and Somatic Mutation Identification of
De Novo AMLs
We used whole-genome sequencing (WGS) to discover somatic
mutations in the unfractionated bone marrow cells of 19 patients
with de novo AML using previously described approaches (Ding
et al., 2012; Ley et al., 2010; Welch et al., 2012). Most of the
assessed AMLs had a normal karyotype (11/18; 61%), and
they encompassed a range of French-American-British (FAB)
subtypes andmutational spectra (Table 1 and Table S1 available
online). All but one of the samples (AML54/UPN161510) have
been analyzed previously by either exome sequencing (14 sam-
ples; Cancer Genome Atlas Research Network, 2013) or WGS
(four samples; Ding et al., 2012; Ley et al., 2008, 2010; Welch
et al., 2012), although samples with existing WGS were reana-
lyzed to identify additional somatic variants. AML-associated
single-nucleotide variants (SNV) and coding insertion-deletion
(indel) mutations discovered by WGS were confirmed using tar-
geted, deep digital sequencing with custom capture arrays
(Tables S1, S2, and S3), which demonstrated high reproducibility
with repeated targeted sequencing of the same bone marrow
samples (Figure S1A). The majority of the identified variants in
each AML sample formed a variant cluster with a variant allele
fraction (VAF) of 45%–50%, which corresponds to heterozygous
somatic mutations present in nearly all cells in the sample; this
variant cluster marks the founding clone, fromwhich all leukemic
cells descend. A smaller number of variants were present in clus-
ters at lower VAFs and represent leukemic subclones that
possess all of the founding clone variants as well as additional
subclonal somatic variants that arose during the evolution of
the tumor (Figure S1B). Although these subclones are derived
from the founding clone and the subclonal variants have lower
VAFs, it is important to note that, in many cases, they represent
the most abundant leukemic cell population in the bone marrow.
Hierarchy of AML Mutations within Peripheral Blood
Cells
AML subcloneswere identified using bonemarrow samples from
AML patients, but leukemic cells also circulate in the peripheral
blood. Peripheral blood involvement can vary substantially
Figure 1. Mutational and Subclonal Comparison of Peripheral Blood and Bone Marrow Leukemia Samples
Unfractionated bone marrow and peripheral blood leukemia samples were characterized by targeted capture followed by deep sequencing.
(A) Similarity of the variant allele fractions (VAFs) of somatic variants for 19 AML cases (all variants with coverage >503 from all samples are shown). Variants
present in coding regions of the genome are shown red, noncoding in gray, and sex chromosome variants in blue.
(B) Four representative cases of the peripheral blood versus the bone marrow samples, demonstrating cases with strong concordance (AML31 and AML28) and
more variable subclonal distributions (AML43 and AML88).
(C) Comparison of the VAFs of recurrent AMLmutations in paired peripheral blood and bonemarrow samples, including codingmutations inDNMT3A; FLT3 (both
ITD and D835); NPMc; and canonical IDH1, IDH2, and KRAS/NRAS mutations.
See also Figure S1 and Tables S1, S2, and S3.
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Functional Properties of AML Subclonesacross patients, and some studies have reported that the allelic
burdens of single AML mutations can be different in the periph-
eral blood and bone marrow (Jilani et al., 2003; Kro¨nke et al.,
2011; Ma et al., 2009). This raises the possibility that AML sub-
clones may differ in their ability to leave the bone marrow and
circulate in the peripheral blood. To determine whether AML
subclones peripheralize in different ways, we used targeted
sequencing to compare the clonal architecture of peripheral
blood samples to concurrently obtained bone marrow samples.
We found a similar clonal architecture in the peripheral blood in
13 of the 19 cases (68%; Figures 1A, 1B, and S1C); the remaining
samples showed small but significant relative differences (Fig-
ure S1C). However, all variants detected in the bone marrow
sample were present in the peripheral blood, including common
recurrent coding mutations associated with AML (Figure 1C).
The founding clone variants were commonly present at VAFs
of 50% in the peripheral blood leukemia samples, suggesting
that nearly all cells contained these leukemic variants, despite
variable percentages of leukemic blasts (Table S1). To determine
whether hematopoietic cells other than blasts are derived from
the leukemic clone, we used multicolor flow cytometry to isolate
myeloid blasts (CD45dim, SSlow, and CD33+) and lymphocytes
(CD45bright, SSlow, and CD33) from all 19 cases (Figure 2A);
monocytes (CD45int/bright, SSint, and CD33bright) and maturemyelomonocytic cells (CD45int, SShigh, and CD33dim/neg) were
collected from a subset of cases. These different peripheral
blood populations were then analyzed by targeted deep
sequencing of all known somatic variants (Table S4). As ex-
pected, sorted blasts contained all founding clone variants and
also the vast majority of the subclonal variants identified in
unfractionated marrow (Figure 2B). Surprisingly, somatic vari-
ants were also detected in other purified myeloid cells without
blastic morphology (Figures 2C and S2A), regardless of the
morphologic features of the leukemia (represented by the FAB
subtypes). Whereas some of the variants showed either enrich-
ment or depletion in these cell populations (i.e., those that
appear above or below the line Y = X in Figure 2C; see also Table
S5), the founding clone variants had VAFs of 50%, indicating
they were present in nearly all of the cells analyzed (and thus
are unlikely to represent technical contamination from flow sort-
ing). Although AML is functionally defined by a differentiation
block leading to an accumulation of blasts, some cells clonally
related to the leukemia are still capable ofmyeloid differentiation.
These mature cells are either derived from the leukemic clone or
a related ‘‘preleukemic’’ hematopoietic stem-progenitor cell
(HSPC) (Jan et al., 2012; Kro¨nke et al., 2013; Shlush et al., 2012).
Other studies have shown that lymphocyte populations
can harbor mutations or fusion events identified in concurrentCancer Cell 25, 379–392, March 17, 2014 ª2014 Elsevier Inc. 381
Figure 2. Distribution of Leukemia Variants and Subclones in Peripheral Blood Cells
(A) Representative sample demonstrating the isolation of different cell populations by flow cytometry using a combination of side-scatter, CD45, and CD33, as
well as CD19 and CD3 when sufficient cells were available. *, maturing myelomonocytic cells. Scale bar represents 10 mm.
(B–D) Correlation of the bone marrow VAF with flow-sorted and enriched blasts (B), nonblast, nonlymphocytes, including maturing myelomonocytic cells and
monocytes (C), and lymphocytes (D). Variants present in coding regions of the genome are shown red, noncoding in gray, and sex chromosome variants in blue.
See also Figure S2 and Tables S4, S5, and S6.
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Functional Properties of AML Subclonesmyeloid malignancies (Miyamoto et al., 2000; Smith et al., 2010).
However, we found that themajority of the somatic mutations we
identified in the unfractionated de novo leukemia samples were
either not detected in peripheral blood lymphocytes or were pre-
sent at very low levels (mean VAF = 1.79%; 95%ile VAF = 6.06%;
Figure 2D). This was also true for three cases with separately
collected B and T lymphocytes (Figure S2B). In several cases,
rare variants (99 of 6,805 total variants from all cases; 1.45%)
demonstrated VAFs of >10%, implying they were present in a
substantial fraction of the cells in the lymphocyte pool. The
majority of these occurred in noncoding regions and are there-
fore not likely to be relevant for AML pathogenesis (Table S6).
In one case (AML71), a recurrent AML-associated mutation in
DNMT3A at codon R882 had a VAF of 10.5% (8 out of 68 reads),
but no other cases had previously identified recurrent AML
mutations (Cancer Genome Atlas Research Network, 2013)
with VAFs >10% in the lymphocyte pools. We suspect that the
mutations with higher VAFs in peripheral blood lymphocytes
are present in multipotential HSPCs; these may have been382 Cancer Cell 25, 379–392, March 17, 2014 ª2014 Elsevier Inc.acquired during embryogenesis or early hematopoietic develop-
ment (i.e., not in the leukemic clone) or they arose in a preleuke-
mic HSPC population that can contribute to lymphopoiesis. The
variants with very low VAFs were probably caused by leukemic
contamination of the flow-purified lymphocytes; morphologic
assessment of these samples revealed that 2%–5% of the cells
in the lymphocyte pools had myeloid morphology (Figure S2C).
In addition, low levels of sequence contamination (0.5%–1%;
Figure S2D) occurred among indexed samples that were pooled
together for targeted sequencing.
In sum, these data show that most AML subclones have an
equal propensity to circulate into the peripheral blood. In addi-
tion, the majority of myeloid cells in the peripheral blood are
derived from a common myeloid-skewed, transformed HSPC,
either because this transformed cell defaults toward myeloid dif-
ferentiation or because the AML-causative mutations block the
potential for lymphoid differentiation. A consequence of this is
that the VAFs of founding clone variants in the peripheral blood
samples are influenced not only by the blast percentage, but
Cancer Cell
Functional Properties of AML Subclonesalso by the percentage of ‘‘contaminating’’ normal lymphocytes
in the sample (Figure S2E).
AML Subclones Can Have Distinct Cellular Phenotypes
Although all AML subclones were represented among the
different myeloid populations in the peripheral blood samples
(Table S5), some cases showed dramatic differences in the sub-
clonal architecture in purified cell populations. A particularly
striking example was AML31, an acute monocytic leukemia
characterized by leukemic cells with predominantly monocytic
features (Figure 3A) and only rare blasts (3%) in the peripheral
blood. To enhance tracking of subclones in this AML across
samples, we assigned leukemic variants to distinct clusters
using a computational subclone identification method (C.A.M.,
Brian S. White, Nathan D. Dees, M.G., Obi L. Griffith, John
S. Welch, Ravi Vij, Michael H. Tomasson, T.A.G., M.J.W.,
Matthew J. Ellis, William Schierding, J.F.D., T.J.L., E.R.M.,
R.K.W., and Li Ding, unpublished data) that clusters variants
with similar VAFs across multiple samples. This approach iden-
tified three subclones (subclones 1–3): Subclones 1 and 2 were
present in the de novo bone marrow but disappeared at relapse,
and subclone 3 was rare at presentation but dominant at relapse
(Figure 3B; Ding et al., 2012). Targeted sequencing of purified
myeloid blasts from de novo AML31 (identified by dim CD45
expression, low side scatter [SSC], and the presence of Auer
rods: Figure 3A, inset) revealed an enrichment of variants asso-
ciated with subclone 3 (Figure 3C), the main leukemic population
present in the relapse sample. Consistent with this observation,
AML31 exhibited predominantly blastic features at relapse,
rather than the monocytic morphology of the de novo leukemia.
In addition, cells from AML28 with flow characteristics of
maturing myelomonocytic cells (Figure 3D) showed enrichment
of subclonal variants (subclone 4 variants) previously found at
disease relapse (Ding et al., 2012). Characterization of the
myeloid blasts and monocytes in AML87, an acute myelomono-
cytic leukemia (FAB M4), also revealed that different subclones
had distinct morphologic properties (Figure 3E). Whereas such
dramatic enrichment was not observed in all cases (see Figures
2 and S3; Table S5), these data demonstrate that some sub-
clones correspond to distinct populations of cells with character-
istic morphologic and/or immunophenotypic properties. This
implies that some subclones are functionally distinct in their
ability to differentiate into more mature cells.
Single-Cell Genotyping Verifies ImputedAMLSubclones
To confirm the identity of subclones at the single-cell level and to
establish their hierarchy within the tumor, we used an amplicon-
based sequencing approach to genotype the founding clone and
subclonal SNVs in single cells purified by cell sorting. Leveraging
the findings for AML28 (where purified blasts and maturing mye-
lomonocytic cells were enriched for different subclonal variants;
see Figure 3D), we isolated individual cells from total myeloid
cells (excluding lymphocytes) and from maturing myelomono-
cytic cells identified by flow cytometric and immunophenotypic
features (Figures 4A) and verified these populations by morpho-
logic examination (Figure S4A). Whole-genome amplification
was then used to prepare DNA from each cell for subsequent
PCR amplification and sequencing of ten known somatic muta-
tions and nine known heterozygous SNPs (used to assess thefrequency of allele-specific amplification and to establish accu-
rate genotyping criteria; Figures S4B–S4F). The fraction of single
cells harboring each of the ten leukemic variants was in close
agreement with predictions based on the variant allele fractions
found in the unfractionated sample (Figures 4B and 4C). Found-
ing clone variants and variants in subclones 1 and 2were present
in the majority of the purified myeloid cells, but subclone 4 vari-
ants were not detected in the total myeloid cell pool (Figure 4B).
In contrast, subclone 4 variants were significantly enriched in the
purified maturing myelomonocytic cells (Figure 4C). We next
assembled the genotypes for each individual cell to establish
the relationships of the subclonal variants within the tumor.
This demonstrated that the predominant genotype among all
myeloid cells included variants in subclones 1 and 2, in addition
to founding clone variants; cells with subclone 1, 2, and 3 vari-
ants were the next most common (Figure 4D). It also established
that subclone 3 arose from subclone 2 and implied the existence
of an ancestral cell that contained only subclone 1 and founding
clone variants. The subclone 4 genotype was most common in
cells with the maturing myelomonocytic phenotype and arose
directly from the founding clone, i.e., independently from sub-
clones 1, 2, and 3 (Figure 4E). We also performed genotyping
of single cells isolated from the unfractionated peripheral blood
of AML31, which also confirmed the allele fractions and subclone
genotypes imputed from the unfractionated bone marrow sam-
ple (Figures 4F and 4G).
Some AML Subclones Have Unique Functional
Properties In Vitro
The findings noted above suggest that some subclones have
distinct functional properties, including different capacities for
hematopoietic differentiation in vivo. In addition, the presence
of multiple subclones in some samples implies that these sub-
clonal populations may have cell-intrinsic advantages that allow
them to expand faster than the founding clone. To determine
whether subclones have different growth properties in an exper-
imental system, we used an established in vitro stromal cocul-
ture method (Klco et al., 2013) to expand three different de
novo AML samples with well-defined subclonal populations at
presentation and relapse (AMLs 1, 31, and 43; Ding et al.,
2012). These de novo AML samples were cultured on stromal
cells in the presence of human hematopoietic cytokines for
7 days (Figures 5A and 5B) and then analyzed by targeted
sequencing of all known variants in these genomes. Although
the subclonal composition of AML1 (Figure 5C), AML43 (Fig-
ure 5D), and AML88 (Figure S5A) were stable after 1 week of
expansion, the subclonal architecture of AML31 changed
dramatically—subclone 3 variants showed substantial enrich-
ment in culture, increasing from a mean VAF of 2% to almost
20% within 7 days (Figures 5E and S5B). As described above,
this subclone was highly enriched in myeloid blasts and was
also the dominant subclone at relapse.
Preferential Subclone Engraftment in
Immunodeficient Mice
Xenotransplantation studies are commonly used to study func-
tional heterogeneity of primary AML samples, including the iden-
tification of phenotypes associated with leukemia-initiating cell
populations. To examine the patterns of subclonal engraftmentCancer Cell 25, 379–392, March 17, 2014 ª2014 Elsevier Inc. 383
Figure 3. Subclonal Enrichment in Distinct Myeloid Subpopulations
(A) Cells from AML31 were flow-sorted, and distinct morphologic populations were confirmed by morphologic examination. Note Auer Rod present in the
myeloblast (*). Scale bar represents 10 mm.
(B) Clonality plot demonstrating the relationship of the de novo AML31 tumor and the relapse leukemia (Ding et al., 2012). Important coding mutations are
highlighted.
(C–E) Clonality plots demonstrating the relationship of the de novo leukemias to different cell populations; (C) AML31, blasts (top) and monocytes (bottom);
(D) AML28, blasts (top) and maturing myelomonocytic cells (bottom); and (E) AML87, blasts (top) and monocytes (bottom). For all clonality plots, only variants in
computationally identified clusters (SciClone; C.A.M., Brian S. White, Nathan D. Dees, M.G., Obi L. Griffith, John S.Welch, Ravi Vij, Michael H. Tomasson, T.A.G.,
M.J.W., Matthew J. Ellis, William Schierding, J.F.D., T.J.L., E.R.M., R.K.W., and Li Ding, unpublished data) that are diploid (copy number = 2) and with coverage
depth >503 are shown.
See also Figure S3.
Cancer Cell
Functional Properties of AML Subclonesfollowing xenotransplantation, we transferred cells from nine
different AML samples into unconditioned immunodeficient
mice (one million viable cells/mouse via lateral tail vein injec-
tions), including six samples that were concurrently injected384 Cancer Cell 25, 379–392, March 17, 2014 ª2014 Elsevier Inc.into mice from the NOD-scid-IL2Rgnull (NSG) strain (Ito et al.,
2002; Sanchez et al., 2009; Sarry et al., 2011) and also the
NSG-SGM3 strain (Wunderlich et al., 2010), which expresses
the human hematopoietic cytokines stem cell factor, granulocyte
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Functional Properties of AML Subclonesmacrophage-colony stimulating factor, and interleukin 3; cells
from AML1, AML62, and AML88 were injected only into NSG-
SGM3 mice. A total of 73 mice (31 NSG and 42 NSG-SGM3)
were injected; mice were sacrificed at 12–16 weeks or at the first
sign of illness. Eight of the nine AML samples engrafted, with the
NSG-SGM3 strain achieving equivalent or higher engraftment
efficiencies in all cases, as expected (Figure S6A; Table S6).
To assess the subclonal composition of the xenografts, human
leukemia cells were purified from 52 bone marrow xenografts by
flow cytometry using antibodies to human CD45, CD33, and/or
CD34 for subsequent sequencing. Flow cytometric characteriza-
tion showed substantial immunophenotypic variability among
the xenografts that was in part dependent on the mouse strain
used. For example, AML31 xenografts (n = 11) showed higher
CD34 expression in NSG-SGM3 mice compared to NSG mice
(Figure 6A). Sequence analysis of AML31 xenografts revealed
that subclone 3 was the dominant cell type in all five NSG-
SGM3 mice (mean VAF 37%–46%), whereas the majority of
the NSG animals (5/6) preferentially engrafted with subclone 1
(Figure 6B), which was the most abundant cell type in the de
novo sample. This pattern supports the single-cell analysis of
AML31, which showed that subclones 1 and 3 arose from the
founding clone independently; accordingly, variants assigned
to subclones 1 and 3 were mutually exclusive in the xenografts
and were never present at similar allele fractions. These results
also suggest that subclone 3 possesses a cell-intrinsic functional
advantage, which appears to be enhanced by the cytokinemilieu
of the NSG-SGM3 mice; it was able to engraft and outcompete
other subclones, despite being present in only a small fraction
of the total cells in the injected sample (mean VAF: 2.5%).
Notably, all the xenografts had significant subclonal restriction,
and no xenografts had a subclonal architecture that was iden-
tical to that of the input leukemia.
Immunophenotypic and sequence analysis of the xenografts
from the other seven AML samples also demonstrated subclonal
restriction (Figures S6B and S6C). In addition, immunopheno-
typic differences between the xenografts obtained from identical
human AML samples injected into NSG and NSG-SGM3 mice
were observed in other cases. For example, AML63 xenografts
from NSG mice consistently displayed a CD34+CD33 immuno-
phenotype, whereas xenografts obtained fromNSG-SGM3mice
were CD34CD33+ (Figure S6B). In contrast to AML31, all of the
AML63 xenografts were composed of the same subclone, sug-
gesting that, in this sample, the same initiating subclone can
display disparate surface antigenmarkers based on the cytokine
milieu in which it develops.
The studies noted above tracked variants previously discov-
ered byWGS (mean coverage303), which has a limit of detec-
tion for somatic variants of 10%. Thus, some rare variants that
became dominant in the xenografts were probably below the
limit of detection in the primary sample examined by whole-
genome sequencing. In addition, previous studies have sug-
gested that mutations can arise during passaging of human cells
in immunodeficient mice (Li et al., 2013). To discover additional
somatic variants within the engrafted subclones, we performed
targeted capture sequencing of the 264 genes that are recur-
rently mutated in AML and other myeloid neoplasms (Cancer
Genome Atlas Research Network, 2013). In most cases, there
were no mutations in the xenografts that had not been identifiedin the initial tumor. However, we discovered a canonical IDH1
R132H mutation in all six of the AML62 xenografts (mean VAF
of xenografts: 45.86%; range: 36.84%–58.44%). In retrospect,
this mutation was then detected in the de novo sample
(5.44%; 8 of 147 reads). Similar analysis demonstrated that
this variant occurred at the level of sequencing errors (1 of 156
reads) in the relapse sample (Figure S6D). This implies that a
rare subclone in the de novo AML sample containing this IDH1
variant preferentially engrafted in 6/6mice, but did not contribute
to the relapse in this patient; this pattern contrasts with what was
observed for AML31, where a rare subclone with enhanced
engraftment properties emerged at relapse. Lastly, only one
xenograft (AML94, NSG3) contained a xenograft-specific muta-
tion (TP53, e8-1; splice site mutation) that may have pathologic
significance.
In sum, xenotransplantation of de novo AML samples resulted
in skewing of the subclonal architecture in all samples, implying
that genetically defined subclones usually represent the domi-
nant engrafting cell population in an individual mouse. We de-
tected subclones in 38 of the 52 xenografts from the eight AML
samples. Most commonly, we observed engraftment by a single
subclone (27 of 38 xenografts had only a single subclone with a
mean VAF >5%). Of the 27 xenografts with monoclonal engraft-
ment, 12 demonstrated engraftment and outgrowth of a minor
subclone in the primary sample.
DISCUSSION
Studies of genetic heterogeneity in cancer thus far have focused
on identifying the somatic variants that mark tumor subclones as
a way to understand the origin, population dynamics, and evolu-
tionary history of a tumor. However, it is not yet clear whether
genetically defined tumor subclones possess unique phenotypic
and/or functional properties that may explain some aspects of a
tumor’s history and perhaps predict its future potential for
relapse or resistance to therapy. Here, we used WGS followed
by capture-based targeted deep sequencing to define the clonal
architecture of unfractionated bone marrow cells of AML pa-
tients and then to follow these subclones after experimental
manipulation. We purified individual cell populations with well-
established cellular phenotypes and found that most myeloid
cells in the peripheral blood at the time of AML diagnosis (even
those that were morphologically nonblastic) were derived from
the AML founding clone; in some cases, genetically defined sub-
clones corresponded to distinct cell populations that could be
identified by cell-surface markers. We also used xenotransplan-
tation of unmanipulated tumor samples in immunodeficient mice
(a mainstay in the experimental characterization of primary can-
cer samples) to understand the functional heterogeneity of tumor
subclones and found that only one subclone engrafted in most
mice even thoughmultiple subclones were present in the sample
that was injected. In some instances, the engrafting subclone
represented only a small fraction of the injected cells (<10%),
implying that some subclones have a cell-intrinsic advantage
(due to increased engraftment potential, excess proliferation,
and/or other factors) after transplantation. These observations,
based on tracking tumor subclones with hundreds of somatic
variants in primary AML samples with a variety of different
initiating mutations, show that functional and phenotypicCancer Cell 25, 379–392, March 17, 2014 ª2014 Elsevier Inc. 385
(legend on next page)
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Figure 5. Rare Subclones Can Have Unique In Vitro Growth Properties
Cells were grown in human hematopoietic cytokines in the presence or absence of MS5 stromal cells for 7 days.
(A) Fold change in cell number after 7 days.
(B) Percentage of 5-ethynyl-20-deoxyuridine (EdU)-positive cells; cells were incubated with EdU for the last 18 hr of culture. Mean values (n = 3) are shown; error
bars represent SD.
(C–E) Subclonal architecture of AML1 (C), AML43 (D), and AML31 (E) at day 0 (label: de novo), relapse (Ding et al., 2012), and day 7 of culture (label: in vitro). Each
column shows the VAFs (indicated on the y axis) of founding clone and subclonal variants for each case.
See also Figure S5.
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Functional Properties of AML Subclonesheterogeneity of subclones are manifest not only in experi-
mental systems, but also in primary tumor samples at disease
presentation.
Many studies of functional heterogeneity in leukemia have
used xenotransplantation to characterize leukemia stem cells
(LSCs; also known as leukemia-initiating cells), which are rare
cells that are functionally defined by unique cell-surface markersFigure 4. Single-Cell Genotyping of Primary AML Samples
Individual cells from AML samples 28 and 31 were isolated by flow cytometry, an
amplicon-based sequencing.
(A) Flow-sorting strategy for AML28, in which individual myeloid cells (excluding
(B–G) Single-cell genotyping results. (B), (C), and (F) show the proportion o
unfractionated cells (in blue) and observed in individual cells (in red) for individu
peripheral blood from AML31 (F). For each comparison, the predictions from unfra
(and multiplied by two to correct for heterozygosity), and the observed single-cell
show the 95% binomial confidence interval for each point estimate. (D), (E), and
maturing myelomonocytic cells (E) fromAML28 and peripheral blood from AML31
with each column representing a single observed genotype that consists of at leas
red). The height of the vertical bars and corresponding numbers show the frequen
genotypes observed in more than two cells in each single-cell experiment are sh
likely due to allele ‘‘dropout’’ (due to unequal amplification of the two alleles), wh
Supplemental Experimental Procedures).
See also Figure S4.as well as potential for engraftment and prolonged self-renewal
in immunodeficient mice (Bonnet and Dick, 1997; Jaiswal
et al., 2009; Jin et al., 2009; Lapidot et al., 1994). More recent
studies have found that engraftment is not necessarily restricted
to specific cellular phenotypes, andmodels have been proposed
where the cancer stem cell phenotype is stochastic and subject
to equilibriumwithin the tumor cell population (Gupta et al., 2011;d single-cell genotypes were determined by whole-genome amplification and
lymphocytes) or maturing myelomonocytic cells were collected.
f cells harboring leukemia-associated variants predicted from the VAFs in
al myeloid cells (B) and maturing myelomonocytic cells (C) from AML28 and
ctionated cells used VAFs obtained directly from deep-sequencing read counts
proportions were obtained from single-cell genotyping experiments. Error bars
(G) show single-cell genotype frequencies from sorted myeloid cells (D) and
(G). The bottom panel in each figure shows the observed single-cell genotypes,
t one of the founding clone or subclonal variants in each subclone (indicated in
cy and absolute number of cells with the indicated genotype, respectively. Only
own; additional genotypes were also observed in low numbers of cells that are
ich we estimated to be 30% using control data from heterozygous SNPs (see
Cancer Cell 25, 379–392, March 17, 2014 ª2014 Elsevier Inc. 387
Figure 6. Phenotype and Subclonal Composition of AML31 Xenografts
Mice were injected with unfractionated peripheral blood leukemia cells and followed for 12–16 weeks, at which time cells were harvested from the bone marrow.
(A) Representative examples of the immunophenotypic properties of AML31 xenografts in individual NSG and NSG-SGM3mice. Shown are expression patterns
of human CD34 and CD11b in the human myeloid leukemia cells (mCD45, hCD45+, and CD33+).
(B) Human CD45+CD33+ cells were purified by cell sorting, and DNA was analyzed by targeted deep sequencing of all known somatic variants in the sample. The
VAFs for all founding clone and subclonal variants are shown for each individual AML31 xenograft and the peripheral blood sample (input, far left).
See also Figure S6 and Table S7.
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showing that discreet subclones (not the founding clone) gener-
ally define the engrafting population in individual mice and that
these subclones do not have equal engraftment and/or
outgrowth potential. This argues against a purely stochastic
model of functional diversity, because specific subclones prefer-
entially engrafted in multiple experiments despite their low fre-
quency in the injected sample. However, in some samples, the
engrafting subclone differed across experiments and between
immunodeficient mouse strains (e.g., AML31), demonstrating
that different initiating populations with unique subclonal muta-
tions can exist within a single AML sample. There was also no
consistent relationship between subclone engraftment potential
and the propensity of a subclone to emerge at relapse (see AMLs
62 and 71; Figure S6C). This implies that functional and pheno-
typic properties of LSCs (such as engraftment, self-renewal,
and chemoresistance) are experimentally variable and not
directly related to the evolutionary history of the tumor, suggest-
ing that the selective pressures imparted during xenotransplan-
tationmay not be equivalent to those imparted in vivo. In contrast
to our findings, Clappier et al. (2011) established a relationship
between xenotransplantation potential and T lymphoblastic
leukemia/lymphoma relapse. This discrepancy may reflect
inherent biological differences between these leukemias,
including their disparate patterns of mutations, as well as exper-
imental differences, such as animal conditioning, engraftment
method, and cell dose. Additional studies will be needed to bet-388 Cancer Cell 25, 379–392, March 17, 2014 ª2014 Elsevier Inc.ter define the relationship between engraftment potential and
relapse for hematologic malignancies.
We anticipate that different xenotransplantation and cell
manipulation approaches (i.e., extent of preconditioning, cell
dose, level of immunodeficiency of the recipient mouse, trans-
plantation route/procedure, number of passages, and timing of
analysis posttransplant) could also alter the subclonal architec-
ture of the engrafting tumor (Kelly et al., 2007; McDermott
et al., 2010; Taussig et al., 2008; Wunderlich et al., 2013). In
particular, the number of injected cells may alter the competitive
balance of subclones (Notta et al., 2011), because the frequency
of initiating cells may be variable among different subclones. It is
also possible that more permissive xenotransplantation condi-
tions (such as intrafemoral injections into irradiated recipients)
may provide less selective pressure and allow for engraftment
of multiple subclones. Ultimately, these different experimental
approaches will need to be formally tested in light of the data
presented in this study. Regardless of these uncertainties, our
results do not invalidate the use of xenotransplantation models
to study cancer. However, they do highlight the need for
genomic characterization of tumors both before and after xeno-
transplantation. In fact, this study suggests that xenotransplan-
tation may also be exploited as a means to isolate subclones
for further study.
We were also able to integrate both technical and functional
assays to demonstrate that subclones are unique genetic en-
tities derived from a common ancestral cell (Figure 7). Although
Figure 7. Model of AML31 Subclonal Architecture and Predicted
Phenotypes
Schematic representation of the implications of AML clonal heterogeneity,
based on the integrated analysis of AML31. The ‘‘% of de novo sample’’ values
were calculated from sequencing the unfractionated AML samples and are
consistent with data obtained from the interrogation of individual cells.
Cancer Cell
Functional Properties of AML Subclonesprevious studies of AML and MDS have inferred the clonal archi-
tecture in unfractionated bone marrow samples through the
identification of clusters of mutations with similar VAFs (Ding
et al., 2012; Walter et al., 2012; Welch et al., 2012) and others
have demonstrated the hierarchical nature of cancer at the
single-cell level (Potter et al., 2013), we employed multiple
orthogonal approaches using the same AML samples to verify
the identity and stability of imputed subclones. We observed
that subclonal variants were present at the expected fractions
among a population of single cells and mutations with similar
VAFs in the unfractionated tumor were present in the same indi-
vidual cells. Similarly, individual subclones that engrafted in
immunodeficient mice contained the expected group of variants
for that subclone, in addition to all founding clone mutations.
Lastly, purified cell populations with well-established morpho-
logic and immunophenotypic features corresponded to distinct
subclones in some cases. Some of these resembled normal
differentiating hematopoietic cells, suggesting that some AML
subclones are capable of myeloid differentiation despite har-
boring known AML driver mutations.
In this study, we were not able to define specific genetic deter-
minants that explain the functional heterogeneity among tumor
subclones. The patterns of subclone engraftment we observed
in immunodeficient mice were inconsistent—some leukemias
(e.g., AML31 and AML94) show variable retention (or loss) of
different subclones, whereas others (e.g., AML88 and AML63)
consistently engrafted a single subclone. We did not find that
specific mutations consistently conferred preferential engraft-
ment, nor did we identify new mutations in known leukemia-
associated genes that were clearly responsible for enhanced
engraftment, survival, or proliferation. For example, subcloneswith canonical mutations in the FLT3 tyrosine kinase did not pref-
erentially engraft, despite the fact that this mutation causes
potent activation of this signaling kinase and has been reported
to result in higher engraftment in NSG mice (Sanchez et al.,
2009). The variable presence of key mutations in engrafting sub-
clones would influence results from trials designed to test tar-
geted chemotherapeutic agents in xenografted mice, such as
FLT3 inhibitors (Smith et al., 2012; Williams et al., 2013), or drugs
targeting other mutations that often occur in subclones, such as
those in RAS genes, or IDH1/IDH2 (Losman et al., 2013; Rohle
et al., 2013); clearly, the identity of the engrafting subclone
(and its mutations) will be required to understand the response
to a targeted drug (see Figure 7). However, the association
of genetically defined subclones with enhanced engraftment
potential suggests that some stable feature within these sub-
clones may be responsible for their altered function. Although
these genetic (or epigenetic) factors remain to be discovered, it
is clear that subclones are discrete entities with important func-
tional differences that may be genetically determined.
Although this study focused on AML, these observations likely
extend to the experimental study of cancer in general, as well as
its diagnosis and treatment. The presence of cancer-associated
somatic mutations in cellular populations that are morphologi-
cally benign has implications for diagnostic testing of cancer
samples and the use of phenotypically normal tissue for research
studies. Our finding that mouse xenografts can have a skewed
clonal architecture when compared to the parental tumor means
that functional data obtained from these models, such as the
capacity for self-renewal and chemoresistance, should not be
generalized to the entire tumor or to other subclones that may
contain different mutations without a rigorous genomic analysis
of the xenograft. Integration of xenotransplantation and genomic
data also demonstrates that the LSCs (defined functionally in
immunodeficient mice) and the founding clone of a patient’s
tumor (defined genetically) are not the same; in fact, there
does not appear to be a consistent relationship between the cells
that engraft in mice and the tumor’s evolutionary hierarchy.
There is already some evidence that these conclusions
generalize to other cancer models, because preferential engraft-
ment of rare subclones has been demonstrated in xenotrans-
plantation studies of ALL and breast cancer samples (Anderson
et al., 2011; Ding et al., 2010; Notta et al., 2011), although this
observation has not been true in all studies using solid tumor
models (Kreso et al., 2013; Li et al., 2013). In this study, we
observed engraftment of a rare, previously undetected sub-
clone in one case (AML62), which was only identified through
unbiased sequencing of the xenograft. It is possible that this
approach, along with expression and epigenetic profiling of
xenografts, may provide a mechanism for understanding the
mutations and phenotypes that are under selective pressure
in these model systems. The fact that primary AML samples
(both frommarrow and blood) contain the entire subclonal reper-
toire of the tumor and are therefore not subject to the same
sampling biases of solid tumors suggests that this disease pro-
vides a very powerful platform for understanding the functional
and genetic heterogeneity in cancer. Ultimately, functional and
genetic data will have to be integrated for experimental systems
to accurately model cancer and to develop therapeutic strate-
gies to effectively treat it.Cancer Cell 25, 379–392, March 17, 2014 ª2014 Elsevier Inc. 389
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Primary AML Samples
All cryopreserved AML samples were collected as part of a study approved
by the Human Research Protection Office at Washington University School
of Medicine after patients provided informed consent in accordance with
the Declaration of Helsinki. Informed consent explicit for whole-genome
sequencing was obtained for all patients in this study on a protocol approved
by the Washington University Medical School Institutional Review Board.
Flow Cytometry
Cryopreserved AML cells were thawed as previously described (Klco et al.,
2013). The following human antibodies were used: anti-CD45 PerCP-Cy5.5
(eBioscience; clone 2D1), anti-CD33 phycoerythrin (PE) or antigen-presenting
cell (APC) (eBioscience; clone WM-53), anti-CD19 APC (BD Biosciences;
clone HIB19), anti-CD34 (PE-pool; Beckman Coulter Genomics; PN
IM1459U), anti-CD15 fluorescein isothiocyanate (BD Biosciences; clone
HI98), anti-CD11b BV421 (BD Biosciences; ICRF44), and CD3 V450
(eBioscience; clone OKT3). Live cell populations were discriminated initially
via CD45/SSC scatterplots, and different subpopulations were defined as
follows: blasts, CD45dim/SSClow, CD33+; lymphocytes, CD45bright/SSClow,
CD33; monocytes, CD45int/bright, SSCinter, CD33+; and maturing myelomo-
nocytic cells, CD45int, SShigh, CD33dim/neg. When available in sufficient
numbers, lymphocytes were further sorted into CD19+ and/or CD3+ popula-
tions. For NSG experiments, human hematopoietic cells (human CD45
positive) from the bone marrow were separated from murine cells (murine
CD45) via flow cytometry; human cells were further isolated by expression of
either CD33 and/or CD34. Cells were sorted on a modified Beckman Coulter
MoFlo into PBS; genomic DNA (gDNA) was prepared using a QIAamp DNA
mini kit (QIAGEN). For capture experiments, a minimum of 100 ng of gDNA
was required for sequencing. Cytospins were performed using a Shandon
Cytospin 3, and cells were stained using Wright-Giemsa (Sigma). Images
were obtained with an Olympus BX51 microscope equipped with an Olympus
DP26 camera. Morphologic studies were performed by a board-certified
hematopathologist (J.M.K.).
Xenotransplantation Studies
Animals were used in accordance to a protocol reviewed and approved by the
Institutional Animal Care and Use Committee of Washington University. Mice
were produced at Washington University School of Medicine using breeders
obtained from the Jackson Laboratory (NSG stock 005557; NSG-SGM3 stock
013062). Six- to ten-week-old unconditioned mice were injected with one
million viable cells via lateral tail vein route. Mice were treated with antibiotics
for 2 weeks after injection and then followed for 12–16 weeks. For these
studies, engraftment was defined >1% human CD45 and CD33 (or CD34) pos-
itivity at the time of sacrifice. This threshold was determined rather than the
standard of 0.1% (Sarry et al., 2011) to ensure that sufficient material would
be present for downstream analyses. For all NSG/NSG-SGM3 comparisons,
cells from a single cryovial were injected at the same time into age-matched
animals.
Variant Discovery and VAF Measurements
Whole-genome sequencing and capture validation was performed as
described in the Supplemental Experimental Procedures. All variant count
data were obtained from raw BAM files using bam-readcount (https://github.
com/genome/bam-readcount) following filtering of reads for low mapping
quality (<10), low base quality (<10), and reads with more than four mis-
matches. Indel variant counts were obtained separately using a custom script
to align overlapping reads from the raw BAM file to short sequences with either
the reference or alternate indel allele using cross_match (http://www.phrap.
org/phredphrap/phrap.html) and tabulate variant counts based on the highest
scoring alignment to these two sequences. All variant counts and fractions
were manipulated and visualized in R.
ACCESSION NUMBERS
The database of Genotypes and Phenotypes accession number for the AML
tumor sequence variants is phs000159.390 Cancer Cell 25, 379–392, March 17, 2014 ª2014 Elsevier Inc.See Supplemental Experimental Procedures for additional information.
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